肺癌分期与疗效评估:CT、18F-FDG PET/CT、MRI及DWI综述与新视角
本文综述了CT和18F-FDG PET/CT在非小细胞肺癌(NSCLC)和恶性胸膜间皮瘤(MPM)分期与疗效评估中的核心作用,介绍了TNM-8分期系统、RECIST 1.1、改良RECIST、PERCIST 1.0及iRECIST等标准,并讨论了孤立性肺结节的诊断随访指南、MRI新兴应用及人工智能前景。
要点
- CT和18F-FDG PET/CT是NSCLC和MPM分期与疗效评估的核心工具。
- RECIST 1.1用于解剖学疗效评估,PERCIST 1.0用于代谢反应评估。
- 免疫治疗中需警惕假性进展,iRECIST可辅助识别。
核心结论
- CT和18F-FDG PET/CT在NSCLC和MPM的分期与疗效评估中居中心地位,解剖与代谢评估标准各有优势与局限。
研究设计与样本
- 综述性文章,系统评估CT和18F-FDG PET/CT在NSCLC和MPM分期与疗效评估中的作用,并介绍TNM-8分期系统、RECIST 1.1、改良RECIST、PERCIST 1.0及iRECIST标准。
- 讨论了英国胸科学会和Fleischner指南对孤立性肺结节的管理,以及Brock(基于CT)和Herder(联合18F-FDG PET/CT)模型对恶性潜能的评估。
- 提及全身MRI在NSCLC诊断和分期中的价值,参考近期多中心Streamline L试验。
诊断标准与关键数值
- NSCLC采用TNM-8分期系统,MPM亦采用相应TNM-8分期系统。
- NSCLC疗效评估采用RECIST 1.1,MPM采用改良RECIST。
- 代谢反应评估采用PERCIST 1.0,免疫治疗相关评估采用iRECIST。
- 孤立性肺结节管理参考英国胸科学会指南和Fleischner指南,恶性潜能评估使用Brock(CT)和Herder(18F-FDG PET/CT)模型。
临床应用与阅片要点
- 日常阅片应结合CT形态学与18F-FDG PET/CT代谢信息进行分期和疗效评估。
- 对免疫治疗患者,需注意假性进展可能,必要时采用iRECIST标准。
- 孤立性肺结节可依据Brock或Herder模型评估恶性概率,辅助多学科团队决策。
- MRI(包括DWI)有助于区分肿瘤与放疗所致肺毒性。
局限性
- RECIST 1.1等解剖学标准未评估代谢反应,存在局限性。
- 解剖学和代谢评估标准在免疫治疗患者中应用有限,假性进展可干扰判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in both sexes combined. Recent years have seen major advances in the diagnostic and treatment options for patients with non-small-cell lung cancer (NSCLC), including the routine use of 2-deoxy-2[18F]-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in staging and response evaluation, minimally invasive endoscopic biopsy, targeted radiotherapy, minimally invasive surgery, and molecular and immunotherapies. In this review, the central roles of CT and 18F-FDG PET/CT in staging and response in both NSCLC and malignant pleural mesothelioma (MPM) are critically assessed. The Tumour Node Metastases (TNM-8) staging systems for NSCLC and MPM are presented with critical appraisal of the strengths and pitfalls of imaging. Overviews of the Response Evaluation Criteria in Solid Tumours (RECIST 1.1) for NSCLC and the modified RECIST criteria for MPM are provided, together with discussion of the benefits and limitations of these anatomical-based tools. Metabolic response assessment (not evaluated by RECIST 1.1) will be explored. We introduce the Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST 1.0) to include its advantages and challenges. The limitations of both anatomical and metabolic assessment criteria when applied to NSCLC treated with immunotherapy and the important concept of pseudoprogression are addressed with reference to immune RECIST (iRECIST). Separate consideration is given to the diagnosis and follow up of solitary pulmonary nodules with reference to the British Thoracic Society guidelines and Fleischner guidelines and use of the Brock (CT-based) and Herder (addition of 18F-FDG PET/CT) models for assessing malignant potential. We discuss how these models inform decisions by the multidisciplinary team, including referral of suspicious nodules for non-surgical management in patients unsuitable for surgery. We briefly outline current lung screening systems being used in the UK, Europe and North America. Emerging roles for MRI in lung cancer imaging are reviewed. The use of whole-body MRI in diagnosing and staging NSCLC is discussed with reference to the recent multicentre Streamline L trial. The potential use of diffusion-weighted MRI to distinguish tumour from radiotherapy-induced lung toxicity is discussed. We briefly summarise the new PET-CT radiotracers being developed to evaluate specific aspects of cancer biology, other than glucose uptake. Finally, we describe how CT, MRI and 18F-FDG PET/CT are moving from primarily diagnostic tools for lung cancer towards having utility in prognostication and personalised medicine with the agency of artificial intelligence.
引用
- Owens, Hindocha, Lee, et al. The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives. Br J Radiol. 2023. PMID: 37097296. doi:10.1259/bjr.20220339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。